Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Preclearance Of DTC Ads Included In Sen. Kennedy Draft Bill

Executive Summary

Repeat offenders of direct-to-consumer advertising regulations would be required to submit all future ads to FDA for preclearance under a draft bill sponsored by Sen. Edward Kennedy (D-Mass.)

You may also be interested in...



Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

Misleading Drug Ads Should Be Subject To Financial Penalties, AARP Says

Congress should implement financial penalties for misleading drug ads, AARP Executive Director for State & National Initiatives Christopher Hansen said

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel